Edwards Lifesciences (NYSE:EW) Rating Reaffirmed
They currently have a $170 target price on Edwards Lifesciences (NYSE:EW). The target price by Barclays would suggest a potential upside of 3.29% from the company’s close price. This has been announced in a recent report on 10 December.
From a total of 19 analysts covering Edwards Lifesciences Corp (NYSE:EW) stock, 16 rate it a ”Buy”, 1 a “Sell”, and 4 a ”Hold”. This means that 76% of the ratings are positive. The highest target price is $203 while the lowest target price is $134. The mean of all analyst targets is $173.95 with a 3.61% above today’s ($164.5) stock price. Edwards Lifesciences Corp was the topic of 14 analyst reports since July 30, 2015 according to the firm StockzIntelligence Inc. Citigroup initiated shares on November 12 with “Sell” rating. Credit Suisse reinitiated shares with “Outperform” rating and $162 target share price in a report from an August 10. Cowen & Co initiated EW stock in a recent report from October 9 with “Outperform” rating. Finally, UBS initiated the stock with “Buy” rating in a report issued on a September 22.
Approximately 601,208 shares of stock traded hands. Edwards Lifesciences Corp (NYSE:EW) has risen 30.71% since May 7, 2015 and is uptrending. It has outperformed by 32.64% the S&P500.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The company has a market cap of $17.57 billion. The Firm is engaged in the development and commercialization of heart valve therapies. It has 39.05 P/E ratio. It is a maker of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve.
According to Zacks Investment Research, “Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Company’s products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.” Get a free copy of the Zacks research report on Edwards Lifesciences Corp (EW).